 |
市場調査レポート
商品コード
1411452
基底細胞がん治療薬市場：種類別、治療タイプ別、投与経路別、エンドユーザー別-2024-2030年の世界予測Basal Cell Carcinoma Treatment Market by Type (Basosquamous, Morpheaform, Pigmented), Treatment Type (Drug Therapy, Radiation Therapy, Surgery), Route of Administration, End-Users - Global Forecast 2024-2030 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
価格
| 基底細胞がん治療薬市場：種類別、治療タイプ別、投与経路別、エンドユーザー別-2024-2030年の世界予測 |
|
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
|
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
- 全表示
- 概要
- 図表
- 目次
概要
基底細胞がん治療薬市場規模は2023年に64億2,000万米ドルと推計され、2024年には69億3,000万米ドルに達し、CAGR 7.75%で2030年には108億3,000万米ドルに達すると予測されます。
基底細胞がん治療薬の世界市場
| 主な市場の統計 | |
|---|---|
| 基準年[2023］ | 64億2,000万米ドル |
| 予測年[2024］ | 69億3,000万米ドル |
| 予測年 [2030] | 108億3,000万米ドル |
| CAGR（%） | 7.75% |
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは基底細胞がん治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。
市場シェア分析
市場シェア分析は、基底細胞がん治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。
本レポートは、以下の側面に関する貴重な洞察を提供しています：
1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。
2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。
3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。
4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。
5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。
本レポートは、以下のような主要な質問に対応しています：
1-基底細胞がん治療薬市場の市場規模および予測は？
2-基底細胞がん治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？
3-基底細胞がん治療薬市場における技術動向と規制の枠組みは？
4-基底細胞がん治療薬市場における主要ベンダーの市場シェアは？
5-基底細胞がん治療薬市場への参入に適した形態や戦略的手段は？
目次
第1章 序文
第2章 調査手法
第3章 エグゼクティブサマリー
第4章 市場の概要
第5章 市場洞察
- 市場力学
- 促進要因
- 基底細胞がんの世界の有病率
- 病気の早期診断および治療の傾向
- 皮膚がんとその治療に対する意識の高まり
- 抑制要因
- 高額なBCC処理費用
- 機会
- BCC治療の進歩と改善
- 遠隔医療および遠隔皮膚科医療トレンドの新興
- 課題
- 再発と厳格な規制当局の承認に伴う懸念
- 促進要因
- 市場セグメンテーション分析
- 市場動向分析
- 高インフレの累積的影響
- ポーターのファイブフォース分析
- バリューチェーンとクリティカルパス分析
- 規制の枠組み
第6章 基底細胞がん治療薬市場：種類別
- 基底扁平上皮
- 基底細胞
- 色素性
- 表在
第7章 基底細胞がん治療薬市場：治療タイプ別
- 薬物セラピー
- 放射線治療
- 手術
第8章 基底細胞がん治療薬市場：投与経路別
- 経口
- 非経口
第9章 基底細胞がん治療薬市場：エンドユーザー別
- ホームケア
- 病院
- 専門センター
第10章 南北アメリカの基底細胞がん治療薬市場
- アルゼンチン
- ブラジル
- カナダ
- メキシコ
- 米国
第11章 アジア太平洋地域の基底細胞がん治療薬市場
- オーストラリア
- 中国
- インド
- インドネシア
- 日本
- マレーシア
- フィリピン
- シンガポール
- 韓国
- 台湾
- タイ
- ベトナム
第12章 欧州・中東・アフリカの基底細胞がん治療薬市場
- デンマーク
- エジプト
- フィンランド
- フランス
- ドイツ
- イスラエル
- イタリア
- オランダ
- ナイジェリア
- ノルウェー
- ポーランド
- カタール
- ロシア
- サウジアラビア
- 南アフリカ
- スペイン
- スウェーデン
- スイス
- トルコ
- アラブ首長国連邦
- 英国
第13章 競合情勢
- FPNVポジショニングマトリクス
- 市場シェア分析：主要企業別
- 競合シナリオ主要企業別の分析
第14章 競争力のあるポートフォリオ
- 主要な企業プロファイル
- AbbVie Inc.
- Amgen Inc.
- Bausch Health Companies Inc.
- Bayer AG
- Biofrontera AG
- Daiichi Sankyo Company, Limited
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Galderma S.A.
- Genentech, Inc.
- Helsinn Healthcare S.A.
- LEO Pharma A/S
- Medivir AB
- Merck & Co., Inc.
- Novartis AG
- Perrigo Company plc
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Valeant Pharmaceuticals International, Inc.
- 主要な製品ポートフォリオ
第15章 付録
- ディスカッションガイド
- ライセンスと価格について
図表
LIST OF FIGURES
- FIGURE 1. BASAL CELL CARCINOMA TREATMENT MARKET RESEARCH PROCESS
- FIGURE 2. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2023 VS 2030
- FIGURE 3. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. BASAL CELL CARCINOMA TREATMENT MARKET DYNAMICS
- FIGURE 7. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 8. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
- FIGURE 10. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 12. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
- FIGURE 14. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. BASAL CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. BASAL CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
LIST OF TABLES
- TABLE 1. BASAL CELL CARCINOMA TREATMENT MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 6. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY BASOSQUAMOUS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 7. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY MORPHEAFORM, BY REGION, 2018-2030 (USD MILLION)
- TABLE 8. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PIGMENTED, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SUPERFICIAL, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 11. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 15. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 18. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 19. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 20. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CENTRES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 21. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 22. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 23. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 24. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 25. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 26. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 27. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 28. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 29. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 30. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 31. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 32. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 33. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 34. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 35. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 36. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 37. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 38. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 39. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 40. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 41. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 42. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 43. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 44. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 45. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 46. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 47. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 48. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 49. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 50. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 51. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 52. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 53. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 54. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 55. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 56. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 57. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 58. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 59. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 60. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 61. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 62. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 63. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 64. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 65. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 66. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 67. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 68. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 69. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 70. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 71. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 72. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 73. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 74. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 75. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 76. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 77. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 78. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 79. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 80. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 81. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 82. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 83. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 84. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 85. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 86. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 87. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 88. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 89. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 90. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 91. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 92. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 93. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 94. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 95. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 96. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 97. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 98. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 99. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 100. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 101. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 102. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 103. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 104. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 105. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 106. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 107. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 108. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 109. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 110. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 111. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 112. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 113. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 114. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 115. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 116. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 117. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 118. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 119. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 120. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 121. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 122. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 123. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 124. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 125. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 126. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 127. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 128. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 129. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 130. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 131. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 132. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 133. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 134. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 135. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 136. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 137. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 138. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 139. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 140. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 141. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 142. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 143. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 144. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 145. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 146. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 147. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 148. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 149. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 150. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 151. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 152. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 153. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 154. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 155. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 156. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 157. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 158. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 159. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 160. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 161. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 162. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 163. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 164. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 165. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 166. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 167. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 168. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 169. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 170. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 171. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 172. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 173. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 174. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 175. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 176. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 177. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 178. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 179. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 180. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 181. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 182. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 183. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 184. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 185. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 186. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
- TABLE 187. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 188. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 189. BASAL CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
- TABLE 190. BASAL CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 191. BASAL CELL CARCINOMA TREATMENT MARKET LICENSE & PRICING
目次
Product Code: MRR-5C6F41F5B0CD
[193 Pages Report] The Basal Cell Carcinoma Treatment Market size was estimated at USD 6.42 billion in 2023 and expected to reach USD 6.93 billion in 2024, at a CAGR 7.75% to reach USD 10.83 billion by 2030.
Global Basal Cell Carcinoma Treatment Market
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 6.42 billion |
| Estimated Year [2024] | USD 6.93 billion |
| Forecast Year [2030] | USD 10.83 billion |
| CAGR (%) | 7.75% |
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Basal Cell Carcinoma Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Basal Cell Carcinoma Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Basal Cell Carcinoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Daiichi Sankyo Company, Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Galderma S.A., Genentech, Inc., Helsinn Healthcare S.A., LEO Pharma A/S, Medivir AB, Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Valeant Pharmaceuticals International, Inc..
Market Segmentation & Coverage
This research report categorizes the Basal Cell Carcinoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Type Basosquamous
- Morpheaform
- Pigmented
- Superficial
- Treatment Type
- Drug Therapy
- Radiation Therapy
- Surgery
- Route of Administration
- Oral
- Parenteral
- End-Users
- Homecare
- Hospitals
- Specialty Centres
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Basal Cell Carcinoma Treatment Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Basal Cell Carcinoma Treatment Market?
3. What are the technology trends and regulatory frameworks in the Basal Cell Carcinoma Treatment Market?
4. What is the market share of the leading vendors in the Basal Cell Carcinoma Treatment Market?
5. Which modes and strategic moves are suitable for entering the Basal Cell Carcinoma Treatment Market?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
- 4.1. Introduction
- 4.2. Basal Cell Carcinoma Treatment Market, by Region
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Prevalence of basal cell carcinoma worldwide
- 5.1.1.2. Inclination towards early diagnosis and treatment of diseases
- 5.1.1.3. Growing awareness regarding skin cancer and treatments
- 5.1.2. Restraints
- 5.1.2.1. High cost of BCC treatment
- 5.1.3. Opportunities
- 5.1.3.1. Advancements and improvements in BCC treatment
- 5.1.3.2. Emerging trend of telemedicine and teledermatology
- 5.1.4. Challenges
- 5.1.4.1. Concerns associated with recurrence and stringent regulatory approval
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
6. Basal Cell Carcinoma Treatment Market, by Type
- 6.1. Introduction
- 6.2. Basosquamous
- 6.3. Morpheaform
- 6.4. Pigmented
- 6.5. Superficial
7. Basal Cell Carcinoma Treatment Market, by Treatment Type
- 7.1. Introduction
- 7.2. Drug Therapy
- 7.3. Radiation Therapy
- 7.4. Surgery
8. Basal Cell Carcinoma Treatment Market, by Route of Administration
- 8.1. Introduction
- 8.2. Oral
- 8.3. Parenteral
9. Basal Cell Carcinoma Treatment Market, by End-Users
- 9.1. Introduction
- 9.2. Homecare
- 9.3. Hospitals
- 9.4. Specialty Centres
10. Americas Basal Cell Carcinoma Treatment Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
11. Asia-Pacific Basal Cell Carcinoma Treatment Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
12. Europe, Middle East & Africa Basal Cell Carcinoma Treatment Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. AbbVie Inc.
- 14.1.2. Amgen Inc.
- 14.1.3. Bausch Health Companies Inc.
- 14.1.4. Bayer AG
- 14.1.5. Biofrontera AG
- 14.1.6. Daiichi Sankyo Company, Limited
- 14.1.7. Eli Lilly and Company
- 14.1.8. F. Hoffmann-La Roche AG
- 14.1.9. Galderma S.A.
- 14.1.10. Genentech, Inc.
- 14.1.11. Helsinn Healthcare S.A.
- 14.1.12. LEO Pharma A/S
- 14.1.13. Medivir AB
- 14.1.14. Merck & Co., Inc.
- 14.1.15. Novartis AG
- 14.1.16. Perrigo Company plc
- 14.1.17. Pfizer Inc.
- 14.1.18. Regeneron Pharmaceuticals, Inc.
- 14.1.19. Sanofi S.A.
- 14.1.20. Sun Pharmaceutical Industries Ltd.
- 14.1.21. Valeant Pharmaceuticals International, Inc.
- 14.2. Key Product Portfolio
15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
